A Look At Cellebrite DI (CLBT) Valuation After Q1 2026 Earnings And New Growth Guidance - simplywall.st

Q1 2026 results and new guidance put Cellebrite DI (CLBT) in focus Cellebrite DI (NasdaqGS:CLBT) is back on investors’ radar after reporting first quarter 2026 results and issuing second quarter revenue guidance, alongside commentary on federal demand and AI driven defense and intelligence opportunities. See our latest analysis for Cellebrite DI. Cellebrite DI’s recent Q1 results and new Q2 revenue guidance land after a mixed run for the stock, with the share price down 24.89% year to date and the 1-year total shareholder return down 20.66%, despite a very large 3-year total shareholder return that points to earlier strong gains and more recent loss of momentum. If you are weighing Cellebrite’s AI and defense themes against other opportunities, it can help to compare with a wider group of AI focused small caps using our stock screener, starting with 34 AI small caps With the stock down sharply this year yet trading below analyst targets and a modeled intrinsic value, markets seem cautious despite double digit revenue growth. Is Cellebrite now a mispriced opportunity, or is future growth already in the price? Most Popular Narrative: 38.2% Undervalued Against a last close of $13.40, the most followed narrative pegs Cellebrite DI's fair value at $21.67, framing a wide valuation gap that hinges on long term subscription growth and margin assumptions. The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration, improves revenue visibility, predictability, and operating leverage. This is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations. Read the complete narrative. If this valuation spread has your attention, the real story sits in how fast revenues scale, how margins evolve, and what earnings multiple this narrative assumes. Result: Fair Value of $21.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on federal demand returning to more typical levels and on Cellebrite keeping up with tightening privacy rules, both of which could pressure growth, margins and investor confidence. Find out about the key risks to this Cellebrite DI narrative. Another View: Multiples Paint a Tighter Picture There is a clear tension between the 38.2% undervaluation implied by fair value of $21.67 and what today’s earnings multiple suggests. Cellebrite trades on a P/E of 46.8x, compared with 26.7x for the US Software industry and a fair ratio of 30x, which points to richer pricing and less margin for error if growth or sentiment wobble. For investors, that gap between current P/E, peers at 26.7x and a 30x fair ratio can be read as either a quality premium or valuation risk, depending on how confident you are in future execution and AI driven demand. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:CLBT P/E Ratio as at May 2026 Next Steps If this mix of optimism and caution has you thinking hard about Cellebrite, now is the time to look at the underlying numbers yourself and move quickly. To understand what has investors optimistic, take a closer look at the 3 key rewards. Looking for more investment ideas? If Cellebrite has sharpened your thinking, do not stop here; broaden your watchlist now so you are not catching up after the next move. Spot potential value early by scanning screener containing 21 high quality undiscovered gems with solid fundamentals before they land on everyone else's radar. Strengthen portfolio resilience by focusing on companies in the solid balance sheet and fundamentals stocks screener (46 results) that can better handle tougher conditions. Target income opportunities by reviewing the 10 dividend fortresses that combine higher yields with a focus on stability. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Valuation is complex, but we're here to simplify it. Discover if Cellebrite DI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition. Access Free Analysis Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com